KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Common Equity: 2009-2024

Historic Common Equity for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $60.7 million.

  • Nektar Therapeutics' Common Equity rose 74.06% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year increase of 74.06%. This contributed to the annual value of $60.7 million for FY2024, which is 53.63% down from last year.
  • As of FY2024, Nektar Therapeutics' Common Equity stood at $60.7 million, which was down 53.63% from $131.0 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Common Equity registered a high of $1.1 billion during FY2020, and its lowest value of $60.7 million during FY2024.
  • Moreover, its 3-year median value for Common Equity was $131.0 million (2023), whereas its average is $186.1 million.
  • Data for Nektar Therapeutics' Common Equity shows a maximum YoY slumped of 64.27% (in 2023) over the last 5 years.
  • Nektar Therapeutics' Common Equity (Yearly) stood at $1.1 billion in 2020, then plummeted by 36.92% to $679.5 million in 2021, then tumbled by 46.04% to $366.6 million in 2022, then tumbled by 64.27% to $131.0 million in 2023, then tumbled by 53.63% to $60.7 million in 2024.